These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38710155)

  • 41. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
    Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
    J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol.
    Fuh L; Goldstein JN; Hayes BD
    J Thromb Thrombolysis; 2020 Jul; 50(1):217-220. PubMed ID: 31707622
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
    Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
    Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis.
    Abdoellakhan RA; Miah IP; Khorsand N; Meijer K; Jellema K
    Neurocrit Care; 2017 Feb; 26(1):64-69. PubMed ID: 27052728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
    Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
    J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage.
    Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME
    Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
    Grandhi R; Newman WC; Zhang X; Harrison G; Moran C; Okonkwo DO; Ducruet AF
    World Neurosurg; 2015 Dec; 84(6):1956-61. PubMed ID: 26341438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding.
    Arachchillage DRJ; Alavian S; Griffin J; Gurung K; Szydlo R; Karawitage N; Laffan M
    Br J Haematol; 2019 Mar; 184(5):808-816. PubMed ID: 30515764
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series.
    Reynolds TR; Gilbert BW; Hall KM
    J Pharm Pract; 2021 Oct; 34(5):755-760. PubMed ID: 32089040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding: A qualitative systematic review.
    Phillips A; Bradley C; Cash J; Sangiovanni R; Wingerson C
    Am J Health Syst Pharm; 2024 May; 81(11):e274-e282. PubMed ID: 38430127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis.
    White CM; Caroti KS; Bessada Y; Hernandez AV; Baker WL; Dobesh PP; van Haalen H; Rhodes K; Coleman CI
    Pharmacotherapy; 2024 May; 44(5):394-408. PubMed ID: 38721837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing.
    Chiasakul T; Crowther M; Cuker A
    Res Pract Thromb Haemost; 2023 Feb; 7(2):100107. PubMed ID: 37063756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate for Bleeding Complications of Vitamin K Antagonists-The PROPER3 Randomized Clinical Trial.
    Abdoellakhan RA; Khorsand N; Ter Avest E; Lameijer H; Faber LM; Ypma PF; Nieuwenhuizen L; Veeger NJGM; Meijer K
    Ann Emerg Med; 2022 Jan; 79(1):20-30. PubMed ID: 34535300
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dosing of 3-factor prothrombin complex concentrate for international normalized ratio reversal.
    Baggs JH; Patanwala AE; Williams EM; Erstad BL
    Ann Pharmacother; 2012 Jan; 46(1):51-6. PubMed ID: 22190253
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reversal or Repletion Treatment Strategies and Outcomes of Patients With Major Bleeding Events Managed in the Emergency Department: Large Real-Life Investigation in the Northwestern Healthcare District of Tuscany.
    Conti A; Leorin M; Bogazzi IC; Renzi N; Pepe G; Frosini F; Furesi L; Dalla Tomasina L; Pennati P; Ghiadoni L;
    Crit Pathw Cardiol; 2024 Jun; 23(2):58-72. PubMed ID: 38781079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings.
    Hitchcock ZR; Smith SD; Le LT; Lees LR; Brandt MD
    J Pharm Pract; 2023 Apr; 36(2):221-226. PubMed ID: 34231410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors.
    Tao J; Bukanova EN; Akhtar S
    J Intensive Care; 2018; 6():34. PubMed ID: 29942519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Four-Factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants.
    Zada I; Wang S; Akerman M; Hanna A
    J Intensive Care Med; 2021 Jan; 36(1):58-62. PubMed ID: 31746285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria.
    Dev P; Abousaab C; Zhou C; Sarode R
    J Thromb Thrombolysis; 2022 Feb; 53(2):249-256. PubMed ID: 34373984
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding.
    Sheikh-Taha M; Crawley RM
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):295-299. PubMed ID: 31709499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.